Abstract: A method for improving the retention between the surfaces of medical devices. The method includes coating a surface of one medical device such as a stent with a coating that includes a functional group and coating a surface of another medical device such as a balloon with a coating that includes an identical or different functional group. The method further includes interacting the coated surfaces to produce a plurality of bonds between the surfaces, thereby improving retention.

Abstract: Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is paclitaxel, rapamycin, or paclitaxel and rapamycin. The first additive is a surfactant. The second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups.

Abstract: Effective treatments of acute pain for extended periods of time are provided. Through the administration of an effective amount of dexamethasone at or near a target site, one can relieve pain cause by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least twenty-five days. In some embodiments, the relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

Abstract: The present invention provides methods of administering an active agent to a specifically identified area of mucous membrane of a human being, as well as a body dissolving film formed therefore.

Abstract: A biodegradable, multi-layered controlled release gastroretentive dosage form which is optionally divided into a first dosage of zaleplon for controlled release and a second dosage of zaleplon for immediate release in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates upon contact with gastric juice and the gastroretentive dosage form unfolds rapidly upon contact with gastric juice. The biodegradable, multi-layered gastroretentive dosage forms of the invention provide efficient sleep induction with good sleep maintenance and minimal next day residual effects.

Abstract: The invention relates to a coated medical device for rapid delivery of a therapeutic agent to a tissue in seconds to minutes. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, a contrast agent, and an additive.

Abstract: The present invention, as described above and as further defined by the claims, provides methods of administering an active agent via adhesion of a film to a mucous membrane in the oral cavity of a mammal, as well as and ODF formed therefore. An active agent may be ingested as the ODF dissolves resulting in systemic treatment of the mammal. In additional embodiments, an ODF may provide topical administration of an active agent.

Abstract: A dialysis acid precursor assembly including a dialysis acid precursor composition of dry components including anhydrous glucose, a dry acid, a magnesium chloride 4.5-hydrate (MgCl2.4.5H2O) and a potassium salt or calcium salt, and a moisture-resistant container with a water vapor transmission rate less than 0.2 g/m2/d at 38° C./90% RH, wherein the dialysis acid precursor composition is sealed within the container.

Abstract: The invention provides polymer compositions for cell and drug delivery.

Abstract: The present invention relates to compositions and methods for modulating melanin production, secretion and/or accumulation in human skin cells. In particular, the present invention relates to the use of A3 adenosine receptor antagonists in compositions and methods for the treatment and amelioration of hyper-pigmentation conditions and for the lightening of skin, and to the use of A3 adenosine receptor agonists in compositions and methods for the treatment and amelioration of hypo-pigmentation conditions and for the tanning of skin.

Abstract: Based on the present disclosure, a minimal time interval can be achieved between the last ingestion of a picosulfate composition and the performance of the colonoscopy. For example, the present disclosure is directed to a method of timing a colonoscopy procedure performed on a patient in need thereof, comprising: administering, to the patient, a picosulfate bowel composition kit according to the kit's instructions; performing the procedure less than about 4 hours after the administration of the kit.

Abstract: The present disclosure describes an implant for tissue replacement or augmentation including a resorbable non-pyrogenic porous body of irradiated oxidized cellulose, formed from a precursor reactive mixture of irradiated cellulose and an oxidizing agent, where the body forms a heterogeneous three-dimensional fibrillar network. Also disclosed is a method for producing a body of oxidized cellulose including irradiating a body of cellulose to form an irradiated body of cellulose, and reacting the irradiated body of cellulose with an oxidizing agent to form a non-pyrogenic porous and resorbable body of oxidized cellulose.

Abstract: The present invention relates to a bar soap composition that contains zinc pyrithione (ZPT) and a metal-pyridine oxide complex, preferably a zinc-pyridine oxide complex. The bar soap may be characterized by enhanced discoloration resistance, extended shelf life, and/or increased anti-microbial efficacy.

Abstract: A wound dressing and a method of making the wound dressing is described herein. The wound dressing is formed of an absorbent substrate formed of one or more layers and a low-adherence layer disposed on the substrate. The low-adherence layer can be disposed within at least a portion of the substrate. The low-adherence layer is formed of a mixture of at least one highly fluorinated polymer and at least one acidic polymer. The at least one highly fluorinated polymer has a fluorine content greater than the fluorine content of the at least one acidic polymer.

Abstract: An aqueous composition includes: (a) surfactants comprising a salt of a C10-16 alcohol ethoxylate sulfate, a betaine surfactant, and an alkyl polyglucoside, wherein the salt of the C10-16 alcohol ethoxylate sulfate is present in a quantity that is greater than any other surfactant; (b) at least 15 weight % of the composition of a C12-18 fatty acid. A cleansing method includes applying the composition to skin or hair and washing, and optionally rinsing with water.

Abstract: The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.

Abstract: The present invention is concerned with a refinement of the processing of particles that are to form a dry powder formulation which is to be administered to the lung using a dry powder inhaler (DPI) device. In particular, the present invention provides the processing of particles of active material and particles of carrier material in the presence of additive material to provide a powder composition which exhibits excellent powder properties and which is economical to produce.

Abstract: Compositions and methods of making a modified polyhydroxylated polymer comprising a polyhydroxylated polymer having reversibly modified hydroxyl groups, whereby the hydroxyl groups are modified by an acid-catalyzed reaction between a polydroxylated polymer and a reagent such as acetals, aldehydes, vinyl ethers and ketones such that the modified polyhydroxylated polymers become insoluble in water but freely soluble in common organic solvents allowing for the facile preparation of acid-sensitive materials. Materials made from these polymers can be made to degrade in a pH-dependent manner. Both hydrophobic and hydrophilic cargoes were successfully loaded into particles made from the present polymers using single and double emulsion techniques, respectively. Due to its ease of preparation, processability, pH-sensitivity, and biocompatibility, of the present modified polyhydroxylated polymers should find use in numerous drug delivery applications.

Abstract: The present invention provides compositions and methods for treatment of abnormal conditions in a subject, wherein the abnormal condition affects the musculoskeletal joints of the subject.

Abstract: The present invention concerns gastroretentive formulation comprising an active substance granulated with a mixture of a weak gelling agent, a strong gelling agent, and a gas generating agent and process for manufacturing said formulation.